Vertex Pharmaceuticals Stock News

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 11:00 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Great. Thank you very much for joining us today.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #ADC--Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals.

Some decisions require lengthy deliberations and extensive analysis. Others don't.

Thousands of stocks trade on U.S. stock exchanges. Even more trade off-the-counter.

Vertex Pharmaceuticals (VRTX -0.45%) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination of headwinds.

What goes up can come down. Most investors have experienced this first-hand with stocks in their portfolio.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 11:00 a.m....

Vertex Pharmaceuticals (VRTX 0.17%) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process.